BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26984957)

  • 1. Monomeric C-reactive protein inhibits renal cell-directed complement activation mediated by properdin.
    O'Flynn J; van der Pol P; Dixon KO; Prohászka Z; Daha MR; van Kooten C
    Am J Physiol Renal Physiol; 2016 Jun; 310(11):F1308-16. PubMed ID: 26984957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properdin Pattern Recognition on Proximal Tubular Cells Is Heparan Sulfate/Syndecan-1 but Not C3b Dependent and Can Be Blocked by Tick Protein Salp20.
    Lammerts RGM; Talsma DT; Dam WA; Daha MR; Seelen MAJ; Berger SP; van den Born J
    Front Immunol; 2020; 11():1643. PubMed ID: 32849563
    [No Abstract]   [Full Text] [Related]  

  • 3. Complement activation by tubular cells is mediated by properdin binding.
    Gaarkeuken H; Siezenga MA; Zuidwijk K; van Kooten C; Rabelink TJ; Daha MR; Berger SP
    Am J Physiol Renal Physiol; 2008 Nov; 295(5):F1397-403. PubMed ID: 18753294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monomeric C-reactive protein modulates classic complement activation on necrotic cells.
    Mihlan M; Blom AM; Kupreishvili K; Lauer N; Stelzner K; Bergström F; Niessen HW; Zipfel PF
    FASEB J; 2011 Dec; 25(12):4198-210. PubMed ID: 21856781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Properdin has an ascendancy over factor H regulation in complement-mediated renal tubular damage.
    Nagamachi S; Ohsawa I; Suzuki H; Sato N; Inoshita H; Hisada A; Honda D; Shimamoto M; Shimizu Y; Horikoshi S; Tomino Y
    BMC Nephrol; 2014 May; 15():82. PubMed ID: 24885016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease.
    Zaferani A; Vivès RR; van der Pol P; Hakvoort JJ; Navis GJ; van Goor H; Daha MR; Lortat-Jacob H; Seelen MA; van den Born J
    J Biol Chem; 2011 Feb; 286(7):5359-67. PubMed ID: 21135110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-specific deletion of Crry from mouse proximal tubular epithelial cells increases susceptibility to renal ischemia-reperfusion injury.
    Miao J; Lesher AM; Miwa T; Sato S; Gullipalli D; Song WC
    Kidney Int; 2014 Oct; 86(4):726-37. PubMed ID: 24850152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial properdin binding contributes to alternative pathway activation at the surface of viable and necrotic cells.
    van Essen MF; Schlagwein N; van den Hoven EMP; van Gijlswijk-Janssen DJ; Lubbers R; van den Bos RM; van den Born J; Ruben JM; Trouw LA; van Kooten C;
    Eur J Immunol; 2022 Apr; 52(4):597-608. PubMed ID: 35092629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement activation by C-reactive protein on the HEp-2 cell substrate.
    Vaith P; Prasauskas V; Potempa LA; Peter HH
    Int Arch Allergy Immunol; 1996 Oct; 111(2):107-17. PubMed ID: 8859218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the alternative pathway of human complement by autologous cells expressing transmembrane recombinant properdin.
    Vuagnat BB; Mach J; Le Doussal JM
    Mol Immunol; 2000 Jun; 37(8):467-78. PubMed ID: 11090881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H.
    Mihlan M; Stippa S; Józsi M; Zipfel PF
    Cell Death Differ; 2009 Dec; 16(12):1630-40. PubMed ID: 19680263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions.
    Ji SR; Wu Y; Potempa LA; Liang YH; Zhao J
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):935-41. PubMed ID: 16456095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factor h and properdin recognize different epitopes on renal tubular epithelial heparan sulfate.
    Zaferani A; Vivès RR; van der Pol P; Navis GJ; Daha MR; van Kooten C; Lortat-Jacob H; Seelen MA; van den Born J
    J Biol Chem; 2012 Sep; 287(37):31471-81. PubMed ID: 22815489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy.
    Thiele JR; Habersberger J; Braig D; Schmidt Y; Goerendt K; Maurer V; Bannasch H; Scheichl A; Woollard KJ; von Dobschütz E; Kolodgie F; Virmani R; Stark GB; Peter K; Eisenhardt SU
    Circulation; 2014 Jul; 130(1):35-50. PubMed ID: 24982116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.
    Williams AL; Gullipalli D; Ueda Y; Sato S; Zhou L; Miwa T; Tung KS; Song WC
    Kidney Int; 2017 Jun; 91(6):1386-1397. PubMed ID: 28139294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloperoxidase directs properdin-mediated complement activation.
    O'Flynn J; Dixon KO; Faber Krol MC; Daha MR; van Kooten C
    J Innate Immun; 2014; 6(4):417-25. PubMed ID: 24355864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement regulation at necrotic cell lesions is impaired by the age-related macular degeneration-associated factor-H His402 risk variant.
    Lauer N; Mihlan M; Hartmann A; Schlötzer-Schrehardt U; Keilhauer C; Scholl HP; Charbel Issa P; Holz F; Weber BH; Skerka C; Zipfel PF
    J Immunol; 2011 Oct; 187(8):4374-83. PubMed ID: 21930971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5.
    Freeley SJ; Popat RJ; Parmar K; Kolev M; Hunt BJ; Stover CM; Schwaeble W; Kemper C; Robson MG
    J Pathol; 2016 Sep; 240(1):61-71. PubMed ID: 27235854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?
    Michels MAHM; Volokhina EB; van de Kar NCAJ; van den Heuvel LPWJ
    Pediatr Nephrol; 2019 Aug; 34(8):1349-1367. PubMed ID: 30141176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.